ERBB2 and breast carcinoma: The 86–92 cohort provided the long-term outcome data required to gather sufficient outcome events for luminal A breast cancer cases and included 64 luminal A, 45 luminal B, and 13 Her2-Enriched PAM50 cases (Fig. 1b).